July 3, 2024 While the market for Ozempic and similar GLP-1 receptor agonists is booming, the high cost of GLP-1 medications has led some insurance companies and employers to limit or completely halt coverage. Previous Post US Weekly Jobless Claims Rise Labor Market Slows Next Post Expansion into new markets and offerings: Where will Citadel Securities go next?
